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Background/Aims: To evaluate the prognostic impact of 
the lymph node ratio (LNR: the ratio of positive lymph nodes 
to the total number of lymph nodes examined) on disease 
recurrence and survival among rectal cancer patients who 
received curative surgery and postoperative chemoradio-
therapy (CRT). Methods: Between 1995 and 2008, 124 
patients with pathologic T3-4 or node-positive rectal cancer 
underwent curative surgery and postoperative CRT. Post-
operative radiotherapy was delivered at a median dose of 
50.4 Gy (range, 45 to 59.4 Gy) for 6 weeks. Chemotherapy 
consisted of a bolus injection of 5-ﬂ  uorouracil and leucovorin 
in the first and last week of radiotherapy (91.9%) or daily 
capecitabine during radiotherapy (8.1%). Further adjuvant 
chemotherapy was administered after chemoradiation. Re-
sults: The median follow-up was 5.1 years. In the multivariate 
analysis, pathologic N (pN) stage and lymphovascular inva-
sion were signiﬁ  cantly associated with disease-free survival 
and disease-specific survival (p<0.05). However, when the 
LNR  with a cutoff value of 0.2 was included as a covariate 
in the model, the LNR was highly signiﬁ  cant (p<0.001), and 
the pN stage lost its signiﬁ  cance (p>0.05). Conclusions: The 
LNR predicts recurrence and survival more accurately than 
pN stage. The pN stage and the LNR should be considered 
together when estimating the risk of disease recurrence 
among rectal cancer patients. (Gut Liver 2012;6:203-209)
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INTRODUCTION
Colorectal cancer is the third most frequently diagnosed 
cancer in Korea
1 and it has been continuously increasing over 
the past two decades with similar trends in the West.
2 In locally 
advanced rectal cancer, curative surgery with neoadjuvant or 
adjuvant chemoradiotherapy (CRT) became standard treatment 
in most clinical institutes. Recent advances that improved the 
outcome of rectal cancer include radical surgical technique in-
corporating total mesorectal excision (TME), CRT and biologic 
therapy.
3 It has not been clearly demonstrated if intensification 
of CRT by adding other chemotherapeutic agents to 5-fluoro-
uracil (5-FU) and leucovorin (LV) regimens or by dose escala-
tion of pelvic radiotherapy to more than 45-50 Gy will improve 
treatment outcome or survival with the price of increased treat-
ment related toxicities.
4,5 Therefore, it is important to determine 
the clinical and pathological factors to predict poor prognosis 
of rectal cancer and define patient subgroups who will benefit 
from intensified therapy. 
Lymph node (LN) involvement and the number of involved 
regional nodes are among the most important prognostic factors 
in rectal cancer. LN ratio (LNR), which is defined as the number 
of positive LNs divided by the total number of LNs examined, 
was introduced as a significant predictor for survival in other 
malignancies.
6-9 However, the evidence is still limited in rectal 
cancer. In the postoperative adjuvant setting, pathologic stage is 
not affected, thus staging is accurate, particularly nodal status. 
In this study, the prognostic impact of LNR-based classification 
was evaluated together with other clinical prognostic factors, 
to determine if it could improve prognostic information when 
compared with the number of positive LNs for rectal cancer pa-
tients who received curative resection and postoperative CRT.204  Gut and Liver, Vol. 6, No. 2, April 2012
MATERIALS AND METHODS 
1. Patients and pretreatment evaluation 
Between 1995 and 2008, a total of 152 rectal cancer patients 
underwent curative surgery and postoperative radiotherapy. 
Among them, 28 patients were excluded from this study (19 had 
local excision, 6 were lost to follow-up, 3 received radiotherapy 
alone). The remaining 124 patients were included in the analy-
sis. All patients had primary rectal cancer of adenocarcinoma. 
To establish the diagnosis and determine staging, patients un-
derwent pre-operative investigations, including digital rectal 
examination, complete blood cell count, liver function analysis, 
serum carcinoembryonic antigen, colonoscopy with biopsy, 
computed tomography (CT) of the abdomen and pelvis and 
bone scan. Chest CT, magnetic resonance imaging of the pelvis 
or liver, and F-18 deoxyfluoroglucose positron emission tomog-
raphy were performed when required. 
2. Treatment
All patients underwent surgery with curative intent by five 
colorectal surgeons. TME was performed in all patients. Surgery 
included low anterior resection or abdominoperineal resection 
(APR) without lateral pelvic node dissection. The pathologic 
stage was determined according to the sixth edition of the 
American Joint Committee on Cancer (AJCC) staging manual.
10 
Adjuvant CRT was scheduled for 4-8 weeks after surgery (me-
Table 1. Clinical and Pathologic Features of the Patients
Characteristic No. of patients % Characteristic No. of patients %
Age, yr
  Median 62 (range, 21-80)
  <60 58 46.8
  ≥60 66 53.2
Gender
  Male 79 63.7
  Female 45 36.3
Distance from anal verge 
  Median 5
  ≥8 38 30.6 
  ≥5, <8  29 23.4 
  ≥0, <5  49 39.5 
  Missing 8  6.5 
Type of surgery
  LAR 72 58.1
  APR 47 37.9
  Others 5  4.0
Differentiation
  Well 12  9.7
  Moderate 107 86.3
  Poorly 5  4.0
Pathologic T stage
  T1 1  0.8
  T2 9  7.3
  T3 103 83.1
  T4 11      8.9
Tumor size, cm
  Median 5 (range, 1.5-15)
  ≤5 63 50.8
  >5 51 41.1
  Missing 10  8.1
Pathologic N stage
  N0 51 41.1
  N1 35 28.2
  N2 38     30.6
LN examined
  Median 18 (range, 6-81)
  <12 34 27.4
  ≥12 88 71.0
  Missing 2  1.6
Lymphovascular invasion
  Yes 55 44.4
  No 69 55.6
Perineural invasion
  Yes 35 28.2
  No 89 71.8
Margin status
  Positive 8  6.5
  Close 15 12.1
  Negative  101 81.5
CEA, ng/mL
  >5 26 21.0
  ≥0, ≤5 71 57.3 
  Missing 27 21.7 
LAR, low anterior resection; APR, abdominoperineal resection; LN, lymph node; CEA, carcinoembryonic antigen. Kim JY, et al: Lymph Node Ratio in Rectal Cancer  205
dian 77 days; range, 30 to 134 days). Postoperative radiotherapy 
was delivered to the whole pelvis at a median dose of 50.4 Gy 
(range, 45 to 59.4 Gy) for 6 weeks. Chemotherapy included bo-
lus injection of 5-FU and LV for the first and last week of radio-
therapy (n=114, 91.9%) or capecitabine administered daily dur-
ing radiotherapy (n=10, 8.1%). Further adjuvant chemotherapy 
(5-FU and LV) was administered after CRT. A total of 6 cycles 
of chemotherapy was administered to 121 patients (97.6%). 
Written informed consent was obtained from all patients before 
treatment. Catholic Medical Center Central Instituional Review 
Board approved the conduct of this retrospective study. 
3. Follow-up and response evaluation
Clinicians evaluated the patients weekly during treatment 
by physical examination and the appropriate blood tests. The 
patients presented for follow-up after 2 weeks and then 1, 2, 3, 
and 6 months after CRT, and then twice per year until 2 years 
post-surgery. After 2 years, patients were followed up annually 
until 5 years post-surgery. 
Treatment outcomes were evaluated as follows. Local failure 
was defined as any recurrence in the pelvic radiation field, and 
distant metastasis as outside the radiation field. Disease-free 
survival (DFS) was calculated from the end of treatment to the 
time of local or distant failure. The survival end event was de-
fined as death from rectal cancer. Disease-specific survival (DSS) 
was censored at the time of death from rectal cancer or at the 
end of follow-up. 
4. Statistical analysis
The probability of survival was calculated using the Kaplan-
Meier method. To evaluate parameters predictive of survival, 
univariate analysis was performed by comparing survival rates 
using the log-rank test. After ascertaining that the LNR was 
significantly associated with DFS and DSS, various LNR cutoffs 
were evaluated, ranging from 0.05 to 0.95 at intervals of 0.05. 
We selected cutoff points by the minimum p-value approach, at 
which the most significant difference in DFS and DSS was ob-
served. 
Variables which attained univariate statistical significance were 
further assessed in multivariate analyses using Cox’s proportional 
hazard model to analyze correlations between various parameters 
and survival probability. The prognostic significance of the LNR 
was evaluated by multivariate analysis with and without LNR as 
covariate. Statistical tests were 2-sided and performed using SPSS 
version 12.0 (SPSS Inc., Chicago, IL, USA). A p-value of less than 
0.05 was considered statistically significant.
RESULTS
The study cohort was comprised of 79 males and 45 females. 
The median age was 62 years (range, 21 to 80 years). The me-
dian number of LNs removed was 18 (range, 6 to 81). Patient 
characteristics are summarized in Table 1. By the minimum 
p-value approach, 0.2 was deemed the cutoff value of LNR at 
which the most significant difference in DFS and DSS was ob-
served. Patients were classified into three groups: patients who 
were LN negative, those with LNR more than 0 and less than 0.2, 
and those with LNR of 0.2 or greater. 
1. Pattern of failure and survival
Median follow-up duration was 5.1 years (range, 0.4 to 16.0 
years). Overall, local recurrence developed in 17 patients (13.7%). 
Distant metastases occurred in 35 patients (27.4%). The site of 
distant failure was as follows: liver, 13 patients; lung, 11 pa-
tients; para-aortic LN, 7 patients; peritoneal carcinomatosis, 4 
patients. At the time of analysis, 46 patients had died and 78 
patients were alive. Among 46 deaths, 36 patients died of rectal 
cancer and 10 died of other causes, including cardiac conditions 
and lung cancer. The corresponding Kaplan-Meier estimates 
(±standard error) for 5-year DFS and DSS rate was 68.0±4.3% 
Fig. 1. The disease-free survival (DFS) curve according to the groups 
by lymph node ratio (LNR). The 5-year DFS rates were 89.9±4.3%, 
72.5±7.8%, and 33.4±8.0% with increasing LNRs (p=0.0325).
Fig. 2. The disease-specific survival (DSS) curve according to the 
groups by lymph node ratio (LNR). The 5-year DSS rates were 
87.4±4.8%, 68.1±8.3%, and 35.3±8.1% with increasing LNRs 
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and 66.4±4.4%, respectively. Five-year overall survival (OS) rate 
was 66.5±4.4%.
2. Analysis of prognostic factors for survival
Pathologic N (pN) stage, lymphovascular invasion, perineural 
invasion, and LNR-based classification achieved statistical sig-
nificance in univariate analysis for DFS and DSS. The DFS and 
DSS curves according LNR groups are shown in Figs 1 and 2, 
respectively. The 5-year DFS rate was 89.9±4.3%, 72.5±7.8%, 
and 33.4±8.0% with increasing LNRs (p=0.0325). The 5-year 
DSS rate was 87.4±4.8%, 68.1±8.3%, and 35.3±8.1% with in-
creasing LNRs (p<0.001) (Table 2).
Cox regression analysis was performed to evaluate whether 
the LNR was associated with DFS and DSS. The results of mul-
tivariate analyses are presented in Table 3. pN stage and lym-
phovascular invasion were significant prognostic factors when 
the LNR was not included in the analysis. However, when the 
LNR-based classification was included in the model as a covari-
ate, LNR was highly significant (LNR=0, hazard ratio [HR], 1; 
LNR <0.2, HR, 1.818, confidence interval [CI], 0.619 to 5.339, 
p=0.277; LNR ≥0.2, HR, 5.438, CI, 2.083 to 14.429, p=0.001 for 
DFS and LNR=0, HR, 1; LNR <0.2, HR, 1.295, CI, 0.504 to 3.325, 
p=0.591; LNR ≥0.2, HR, 4.115, CI, 1.807 to 9.373, p=0.001 for 
DSS, respectively). Thus, pN stage lost its significance (p>0.05) 
Table 2. The 5-Year Kaplan-Meier Values for DFS and DSS according to Prognostic Factor
Characteristic
No. of 
patients
5-yr DFS, 
%±SE
5-yr DSS, 
%±SE
Characteristic
No. of 
patients
5-yr DFS, 
%±SE
5-yr DSS, 
%±SE
Age
  <60 58 68.5±0.1 71.8±6.0
  ±60 66 67.7±0.1 61.5±6.2
p=0.8832 p=0.4367 
Gender
  Male 79 67.8±0.1 68.5±5.4
  Female 45 68.6±0.1 62.9±7.4
p=0.7727 p=0.3113
Distance from anal verge 
  ≥8 38 62.5±8.0 66.7±7.9
  ≥5, <8 29 68.6±8.7 59.7±9.6
  ≥0, <5 49 67.2±6.7 67.2±6.7
p=0.6961 p=0.7062
Type of surgery
  LAR 72 71.8±5.4 67.5±5.8
  APR 47 65.8±6.9 68.1±6.8
  Others 5  40.0±22.0  40.0±22.0
p=0.2333 p=0.4442
Differentiation
  Well 12 91.7±8.0 90.0±9.5
  Moderate 107 66.6±4.6 64.7±4.8
  Poorly 5  40.0±22.0  20.0±17.9
p=0.1979 p=0.0945
Pathologic T stage
  T1-2 10 90.0±9.5 90.0±9.5
  T3-4 114 66.1±4.5 64.4±4.6
p=0.1509 p=0.1094
Tumor size, cm
  ≤5 63 67.1±6.1 67.7±6.2
  >5 51 66.5±6.6 64.3±6.8
p=0.7538 p=0.6507
Pathologic N stage
  N0 51 90.1±4.2 87.7±4.7
  N1 35 67.6±8.1 69.2±8.1
  N2     38     38.5±8.1      34.8±8.0
p<0.0001 p<0.0001
LN examined
  <12 34 67.2±8.1 79.3±6.9
  ≥12 88 68.6±4.9 61.4±5.3
p=0.7611 p=0.5117
LNR
  0 50 89.9±4.3 87.4±4.8
  >0, <0.2 33 72.5±7.8 68.1±8.3
  ≥0.2 39 33.4±8.0 35.3±8.1
p=0.0325 p<0.0001
Lymphovascular invasion
  Yes 55 45.7±6.9 44.7±7.0
  No 69 85.4±4.3 83.2±4.6
p<0.0001 p<0.0001
Perineural invasion
  Yes 35 48.0±8.6 47.1±8.6
  No 89 75.8±4.6 73.9±4.8
p=0.0002 p=0.0004
Circumferential margin status
  Positive 8  62.5±17.1  50.0±17.7
  Close 15  80.0±10.3  79.0±10.8
  Negative 101 66.8±4.7 66.1±4.8
p=0.7516 p=0.8360
DFS, disease-free survival; SE, standard error; DSS, disease-specific survival; LAR, low anterior resection; APR, abdominoperineal resection; LN, 
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on multivariate analysis. This means that LNR is a more signifi-
cant prognostic factor than the absolute number of nodes in the 
present analysis. 
We performed the survival analysis based on the LNR in pa-
tients with stage III. The LNR had a prognostic impact on DFS 
and DSS in patients with stage III (p=0.0012 and p=0.0005, 
respectively). The survival outcome was analyzed by the LNR 
in each pN stage. The LNR had a prognostic significance on the 
DFS in patients with pN1. However, for the patients with pN2, 
the LNR was not associated with the survival. It might be attrib-
uted to that the group with pN2 and the LNR <0.2 consisted of 
only 5 patients. The results of above analyses were presented in 
Table 4.
3. Adverse events related to treatment
Acute treatment-related toxicities are summarized in Table 
5. Diarrhea and radiation dermatitis were most frequently ob-
served. No treatment related death was observed. Late toxicity 
developed in 14 patients (11.3%). Among them, 10 patients 
experienced adhesive ileus. Four patients required surgical treat-
ment for adhesiolysis and 6 patients recovered after conserva-
tive care. Chronic rectal spotting was observed in 1 patient and 
it was diagnosed as radiation proctitis by colonoscopy. Skin 
necrosis developed along the perineal scar in 1 patient who 
needed flap surgery. Enterovaginal fistula was observed in 1 
patient who developed vaginal invaded rectal mass and had 
partial vaginectomy with the initial surgery. She recovered after 
Table 3. Multivariate Analysis of the Prognostic Factors for DFS and DSS 
Variable
Without LNR as a covariate With LNR as a covariate
DFS DSS DFS DSS
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
LVI
  No  1 1 1 1
  Yes  2.934
(1.391-6.190)
0.005 3.053
(1.544-6.037)
0.001 2.686
(1.265-5.703)
0.010 2.833
(1.425-5.636)
0.003
PNI
  Negative  1 1 1 1
  Positive  1.556
(0.783-3.091)
0.207 1.459
(0.752-2.830)
0.264 1.610
(0.828-3.129)
0.160 1.523
(0.808-2.874)
0.194
Pathologic N
  N0 1 1 1 1
  N1 2.234
(0.800-6.244)
0.125 1.434
(0.577-3.563)
0.438 1.808
(0.608-5.376)
0.287 1.234
(0.469-3.247)
0.670
  N2 4.895
(1.853-12.930)
0.001 3.938
(1.728-8.975)
0.001 2.059
(0.574-7.378)
0.268 1.938
(0.632-5.936)
0.247
LNR
  0 11
  >0, <0.2 1.818
(0.619-5.339)
0.277 1.295
(0.504-3.325)
0.591
  ≥0.2 5.483
(2.083-14.429)
0.001 4.115
(1.807-9.373)
0.001
LNR, lymph node ratio; DFS, disease-free survival; DSS, disease-specific survival; HR, hazard ratio; CI, confidence interval; LVI, lymphovascular 
invasion; PNI, perineural invasion.
Table 4. DFS and DSS Rates Indicated by the LNR in Patients with 
Stage III Cancer
Stage III
No. of
patients
Kaplan-Meier estimates, 
%±SE
5-yr DFS 5-yr DSS
All patients LNR
33   >0, <0.2 72.5±7.8 68.1±8.3
39   ≥0.2 33.5±8.0 35.3±8.1
p-value 0.0012 0.0005
pN1 LNR
28   >0, <0.2 74.6±8.3 69.5±9.0
  6   ≥0.2 33.3±19.3 62.5±21.4
p-value 0.0128 0.0883
pN2 LNR
  5   >0, <0.2 60.0±22.0 60.0±22.0
33   ≥0.2 34.9±8.6 30.5±8.5
p-value 0.3564 0.1827
SE, standard error; DFS, disease-free survival; DSS, disease-specific 
survival; LNR, lymph node ratio; pN, pathologic N stage.208  Gut and Liver, Vol. 6, No. 2, April 2012
surgical repair of the fistula.
DISCUSSION
The most widely used staging system for colorectal cancer is 
the AJCC tumor, nodes, metastasis (TNM) classification system, 
which classifies patients into prognostic groups according to the 
depth of the primary tumor, presence of regional LN metastases, 
and evidence of distant metastases. Recently, the AJCC TNM 
stage was updated and the T and N stages were further speci-
fied to improve prognostic capacity. More emphasis has been 
made to the number of retrieved malignant LNs. Accordingly, 
pN1 (metastasis in 1 to 3 regional LNs) has been subdivided into 
pN1a (metastasis in 1 regional LN) and pN1b (metastasis in 2 to 
3 regional LNs), and pN2 (metastasis in 4 or more regional LNs) 
has been subdivided into pN2a (metastasis in 4 to 6 regional 
LNs) and pN2b (metastasis in 7 or more regional LNs).
11
However, the number of malignant LNs in rectal cancer de-
pends on the number of retrieved LNs, which varies with treat-
ment, patient, and tumor characteristics. There is, in practice, 
wide variation in the surgical extent and LN examination. The 
median LN yield varies from 3.5 to 17 between different pathol-
ogy laboratories and individual pathologists according to the 
Dutch TME trial.
12 Neoadjuvant therapy before surgery, APR 
operation, tumor location in the lower rectum, small tumor size, 
old age, and obesity have been reported to be associated with 
lower LN yield.
12,13
In rectal cancer, the minimum number of nodes to be re-
sected and histopathologically assessed for accurate staging is 
considered between 10 and 14.
11 However, there is a tendency 
for higher number of retrieved nodes to be associated with in-
creased incidence of nodal positivity. As was demonstrated in 
the study of node examination techniques, the fat-clearance 
technique enables upstaging of more than 50% of stage II cases 
to stage III, by allowing the identification and examination of 
previously undetected LNs.
14 Therefore, there is a potential for 
stage migration when an inadequate number of LNs is har-
vested. Patients with inadequate LN dissection could receive 
less efficient adjuvant treatment and it may result in inferior 
treatment outcome. The analysis of Mekenkamp et al.
12 supports 
this hypothesis that node negative patients in whom seven or 
less LNs were examined had lower recurrence free interval than 
patients in whom at least 8 LNs were examined (17% vs 10.7%; 
p=0.016). 
The LNR, which takes into account the extent of LN dissec-
tion, has been investigated in other malignancies previously. 
From the Surveillance, Epidemiology, and End Results (SEER) 
population data, the importance of LNR has been shown at 
many cancer sites, including the esophagus,
7 stomach,
15 and 
corpus uteri.
8 In breast cancer, Vinh-Hung et al.
6 suggested 
that the LNR should be considered an alternative to pN staging 
because of stronger statistical power to predict breast cancer-
specific survival from patient analysis of the Geneva Cancer 
Registry.
6 Similarly, several studies investigated the LNR in 
colorectal cancer. Rosenberg et al.
16 analyzed 3,026 patients 
with colorectal cancer at a single surgical center over a 25-year 
period. The optimal cut-off values for prognostic differentiation 
of LNRs were statistically calculated as 0.17, 0.41, and 0.69. The 
5-year OS was 60.6%, 34.4%, 17.6%, and 5.3% with increasing 
LNRs (p<0.001). The LNR had better prognostic value than pN 
category (p<0.05).
16 These cut-off values (0.17, 0.41, and 0.69) 
were further investigated in a large population based collec-
tive of patients with colorectal cancer (n=27,803). The LNR was 
shown to be a strong independent prognostic factor again.
17 
Kim et al.
18 investigated the impact of LNR in 232 rectal cancer 
patients who received postoperative CRT to determine if this 
ratio is useful for the assessment of prognosis in rectal cancer as 
in colon cancer. Patients were grouped as LNR ≤0.1, LNR ≤0.2, 
LNR ≤0.4 and LNR >0.4. The 5-year survival rate significantly 
decreased as the LNR increased (p<0.001). The LNR was a sig-
nificant prognostic factor for OS on Cox regression analysis.
18 
Performing preoperative CRT before curative resection has the 
oncologic advantage of reduced local recurrence although it did 
not improve OS.
19 However, the total number of retrieved LNs 
may decrease or the proportion of patients with fewer than 12 
LNs examined may increase after preoperative CRT. Peschaud 
et al.
20 investigated the utility of LNR in 307 rectal cancer pa-
tients who received neoadjuvant therapy by dividing them into 
4 groups; LNR=0, LNR=0.01 to 0.07, LNR >0.07 to 0.2, and LNR 
>0.2. In the multivariate analysis, LNR was the most significant 
prognostic factor for both DFS (p=0.006) and OS (p=0.0003), 
whereas presence and absence of metastatic LNs was not. LNR 
remained a significant prognostic factor in patients whom fewer 
than 12 LNs were examined (p=0.0058).
20
The LNR was investigated even in node negative colorectal 
cancer by Oh et al.
21 Immunohistochemical staining with anti-
cytokeratin antibody panel can detect LN micrometastasis in 
node negative cases. This method detected micrometastasis in 
Table 5. Treatment-Related Acute Toxicity according to the Radiation 
Therapy Oncology Group Acute Radiation Morbidity Scoring Scheme
Grade
1234
Hematologic   0   2 0 0
  Hemoglobin
  Leukocytes   2 18 2 0
  Platelets   0    0 0 1
Nausea/Vomiting 12   2 0 0
Gastrointestinal 21 17 3 1
Skin 11 31 6 0
Urinary   0   1 0 0
Liver   0   1 0 0Kim JY, et al: Lymph Node Ratio in Rectal Cancer  209
26.6% of node negative patients by hematoxylin-eosin staining. 
The micrometastasis LNR (mmLNR) was calculated by dividing 
the number of LNs in which LN micrometastasis was detected 
by the total number of resected LNs. mmLNR greater than 0.25 
was significantly associated with low 3-year DFS (p=0.03).
21
The present study has the shortcomings of a retrospective 
analysis with small patient sample size. However, the number 
of retrieved LNs (median 18) was sufficient to evaluate the 
prognostic value of LNRs in rectal cancer patients, although 
47 patients (37.9%) underwent APR which could have reduced 
LN yield. Moreover, this study can be differentiated from other 
studies that the significance of the LNR was analyzed with the 
DSS which could predict the association of the variable and the 
survival outcome more exactly from the viewpoint of rectal 
cancer. The impact of LNRs on recurrence and survival of rectal 
cancer has been confirmed again in this study. To assess the 
prognosis and to make informed decisions about further treat-
ment, accurate staging information is very important for both 
patients and clinicians. Although there is no clear consensus on 
the optimal cutoff points for LNRs required for staging classifi-
cation, the potential advantages of LNRs in the staging system 
as an additive or alternative to the absolute number of positive 
LNs need to be investigated in large prospective studies. 
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